Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
15mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Mektovi is an oral kinase inhibitor primarily prescribed for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It is indicated for treatment in combination with encorafenib.
Mektovi is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. By blocking these proteins, Mektovi inhibits the growth of cancer cells.
Fact Table | |
---|---|
Formula | C17H15BrF2N4O3 |
License | FDA approved |
Bioavailability | Approximately 50% |
Legal status | Prescription only |
Chemical Name | 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-2-(2-methoxyethoxy)-N-methylbenzamide |
Elimination half-life | Approximately 8 hours |
Dosage (Strength) | 15 mg tablets |
Pregnancy | Not recommended; consult a healthcare provider |
Brands | Mektovi |
Protein binding | 97% |
PubChem CID | 49850023 |
MedlinePlus | a617055 |
ChEBI | 134660 |
ATC code | L01EE04 |
DrugBank | DB11974 |
KEGG | D10932 |
Routes of administration | Oral |
The recommended dosage is 45 mg by mouth twice daily in combination with encorafenib. Mektovi can be taken with or without food.
Tell your doctor if you have a history of liver disease. They may need to adjust your Mektovi dose to 30 mg twice daily.
Do not stop or adjust the dosage of Mektovi without speaking to your doctor.
The active ingredient in Mektovi is binimetinib.
There are no significant drug-drug interactions between Mektovi and other medications.
Tell your doctor if you have a history of heart disease starting treatment. Your doctor should assess your heart function before starting treatment, after one month, and then every 2-3 months thereafter.
Tell your doctor if you have a history of a clotting disorder.
Use caution if you have a history of eye disease, lung disease, liver disease, musculoskeletal disease, or bleeding disorders.
Do not Mektovi if you are pregnant or planning to become pregnant.
Common adverse reactions may include:
Mektovi [package insert]. Boulder, CO: Array BioPharma; June 2018.